Table 2.

Evaluation and Identification of Cancer Predisposition Syndromes in Pancreatic Cancer Patients.

Syndrome	# of patients who completed evaluation	Mutation prevalence
Overall	159	24 (15.1%)
HBOC (BRCA1, BRCA2)	151	17 (11.3%) 4 BRCA1 mutations; 13 BRCA2 mutations
Lynch syndrome (MLH1, MSH2, MSH6, PMS2)	36	4 (11.1%) 1 MLH1 mutation; 2 MSH2 mutations; 1 MSH6 mutation
PALB2	48	1 (2.1%)
FAMMM (p16)	17	2 (11.8%)

HBOC = Hereditary Breast and Ovarian Cancer syndrome;

FAMMM = Familial Atypical Multiple Mole Melanoma syndrome